SCHEMBL23218057

SCHEMBL23218057

CCOC(=O)Cc1ccccc1OCc1cccc2ccc(Br)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
LMNA P02545 1/20 0.44
AHR P35869 1/20 0.44
HPGD P15428 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
TBXAS1 P24557 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CFD P00746 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CCR5 P51681 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.41
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218659 0.83 CFD (0.44) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL29852814 0.83 CFD (0.44) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL23218949 0.82 TBXAS1 (0.41) KMT2AMEN1ALDH1A1MAPTTBXAS1
SCHEMBL29592641 0.81 MAOB (0.53) KDM4EALDH1A1LMNATBXAS1CFD
SCHEMBL16397226 0.81 MAOB (0.53) KDM4EALDH1A1LMNATBXAS1CFD
SCHEMBL23218214 0.81 CFD (0.59) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL29853332 0.81 CFD (0.59) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL23218748 0.80 MAPT (0.46) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL29852811 0.80 MAPT (0.46) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL23219259 0.79 TBXAS1 (0.41) KMT2AMEN1MAPTLMNATBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB KMT2A 4445/4885MEN1 1819/4885KDM4E 4172/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB KMT2A 4835/4885MEN1 548/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.